34岁潮汕籍女掌门,拿下100亿医药大单

21世纪商业评论
Yesterday

本文字数:2224|预计4分钟读完后生可畏,喜事连连。记者丨韩璐编辑丨谭璐泰国富豪家族的医药生意,迎来重大突破。3月4日,中国生物制药的掌舵人谢其润签发公告,与全球制药巨头赛诺菲,就一款全球首创的移植领域药物,达成独家授权协议。这笔交易的总价为15.3亿美元,折合人民币超105亿元。谢其润团队将获得1.35亿美元的首付款。未来,基于潜在开发、监管和销售情况,她有望获得最高13.95亿美元的里程碑...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10